“…There is evidence, mainly indirect, that exogenous orally administered CoQ 10 may be incorporated into mitochondria, at least in conditions of partial CoQ tissue deficiency, where it may enhance electron transfer and ATP synthesis with improvement of the disease both in human and animal studies, e.g. in genetic CoQ 10 deficiency [Rötig et al, 2000;Di Giovanni et al, 2001;Quinzii and Hirano, 2010], cardiac failure [Rosenfeldt et al, 2005;Molyneux et al, 2009], Parkinson's disease [Matthews et al, 1998], Alzheimer's disease [Yang et al, 2010], Friedreich's ataxia [Hart et al, 2005], and aging [Xu et al, 2010]. The major problem of CoQ 10 administration is its low bioavailability due to its extreme hydrophobicity [Beg et al, 2010].…”